954 related articles for article (PubMed ID: 33554554)
1. Cytokine "storm", cytokine "breeze", or both in COVID-19?
Lippi G; Plebani M
Clin Chem Lab Med; 2020 Dec; 59(4):637-639. PubMed ID: 33554554
[No Abstract] [Full Text] [Related]
2. The emergence of a new cytokine storm during the COVID-19 pandemic: Multisystem inflammatory syndrome in children.
Yang MC; Tsai CC; Su YT; Wu JR
Kaohsiung J Med Sci; 2021 Mar; 37(3):255-256. PubMed ID: 33400372
[No Abstract] [Full Text] [Related]
3. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
Front Immunol; 2021; 12():749291. PubMed ID: 34867978
[TBL] [Abstract][Full Text] [Related]
4. Hemophagocytic syndrome secondary to SARS-Cov-2 infection: a case report.
Meazza Prina M; Martini F; Bracchi F; Di Mauro D; Fargnoli A; Motta M; Giussani C; Gobbin G; Taverna M; D'Alessio A
BMC Infect Dis; 2021 Aug; 21(1):811. PubMed ID: 34388982
[TBL] [Abstract][Full Text] [Related]
5. Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy.
Jiang Y; Rubin L; Peng T; Liu L; Xing X; Lazarovici P; Zheng W
Int J Biol Sci; 2022; 18(2):459-472. PubMed ID: 35002503
[TBL] [Abstract][Full Text] [Related]
6. Successful recovery of severe COVID-19 with cytokine storm treating with extracorporeal blood purification.
Wang Q; Hu Z
Int J Infect Dis; 2020 Jul; 96():618-620. PubMed ID: 32470601
[TBL] [Abstract][Full Text] [Related]
7. Hemocytometric characteristics of COVID-19 patients with and without cytokine storm syndrome on the sysmex XN-10 hematology analyzer.
Martens RJH; van Adrichem AJ; Mattheij NJA; Brouwer CG; van Twist DJL; Broerse JJCR; Magro-Checa C; van Dongen CMP; Mostard RLM; Ramiro S; Landewé RBM; Leers MPG
Clin Chem Lab Med; 2021 Mar; 59(4):783-793. PubMed ID: 33554540
[TBL] [Abstract][Full Text] [Related]
8. Defining the Cytokine Storm Syndrome of COVID-19: Role of the Clinical Laboratory.
Jialal I; Devaraj S
Ann Clin Lab Sci; 2020 Sep; 50(5):703-705. PubMed ID: 33067221
[No Abstract] [Full Text] [Related]
9. Cytokine storm syndrome in coronavirus disease 2019: A narrative review.
Gao YM; Xu G; Wang B; Liu BC
J Intern Med; 2021 Feb; 289(2):147-161. PubMed ID: 32696489
[TBL] [Abstract][Full Text] [Related]
10. Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i).
Pinheiro MM; Fabbri A; Infante M
Immunotherapy; 2021 Jun; 13(9):753-765. PubMed ID: 33906375
[TBL] [Abstract][Full Text] [Related]
11. Elucidating of oxidative distress in COVID-19 and methods of its prevention.
Barciszewska AM
Chem Biol Interact; 2021 Aug; 344():109501. PubMed ID: 33974898
[TBL] [Abstract][Full Text] [Related]
12. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.
Soy M; Atagündüz P; Atagündüz I; Sucak GT
Rheumatol Int; 2021 Jan; 41(1):7-18. PubMed ID: 32588191
[TBL] [Abstract][Full Text] [Related]
13. The immune checkpoints storm in COVID-19: Role as severity markers at emergency department admission.
Avendaño-Ortiz J; Lozano-Rodríguez R; Martín-Quirós A; Terrón V; Maroun-Eid C; Montalbán-Hernández K; Valentín-Quiroga J; García-Garrido MÁ; Del Val EM; Del Balzo-Castillo Á; Peinado M; Gómez L; Herrero-Benito C; Rubio C; Casalvilla-Dueñas JC; Gómez-Campelo P; Pascual-Iglesias A; Del Fresno C; Aguirre LA; López-Collazo E
Clin Transl Med; 2021 Oct; 11(10):e573. PubMed ID: 34709745
[No Abstract] [Full Text] [Related]
14. Interleukin-1- Receptor Kinase 4 Inhibition: Achieving Immunomodulatory Synergy to Mitigate the Impact of COVID-19.
Gupta A; Chun HJ
Front Immunol; 2021; 12():693085. PubMed ID: 34248990
[No Abstract] [Full Text] [Related]
15. COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel.
Napodano C; Pocino K; Stefanile A; Marino M; Miele L; Gulli F; Basile V; Pandolfi F; Gasbarrini A; Rapaccini GL; Basile U
Scand J Immunol; 2021 Mar; 93(3):e12977. PubMed ID: 32931622
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
17. The cytokine storm and thyroid hormone changes in COVID-19.
Croce L; Gangemi D; Ancona G; Liboà F; Bendotti G; Minelli L; Chiovato L
J Endocrinol Invest; 2021 May; 44(5):891-904. PubMed ID: 33559848
[TBL] [Abstract][Full Text] [Related]
18. Cytokines and COVID-19: friends or foes?
Rokni M; Hamblin MR; Rezaei N
Hum Vaccin Immunother; 2020 Oct; 16(10):2363-2365. PubMed ID: 32841579
[TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory Therapy by Cholinergic and Purinergic Modulation in Multiple Sclerosis Associated with SARS-CoV-2 Infection.
Simões JLB; de Araújo JB; Bagatini MD
Mol Neurobiol; 2021 Oct; 58(10):5090-5111. PubMed ID: 34247339
[TBL] [Abstract][Full Text] [Related]
20. Macrophage Activation and Cytokine Release Syndrome in COVID-19: Current Updates and Analysis of Repurposed and Investigational Anti-Cytokine Drugs.
Iqubal A; Hoda F; Najmi AK; Haque SE
Drug Res (Stuttg); 2021 Apr; 71(4):173-179. PubMed ID: 33434935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
